Search Results
Jun 08, 2026, 06:30 ET Broadridge's Distributed Ledger Repo Achieves 220% Year Over Year Growth; Processes $7.2 Trillion in May
trading of over $15 trillion in tokenized and traditional securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 15,000 associates in 21 countries.For more information about us, please visit
More news about: Broadridge Financial Solutions, Inc.
Jun 08, 2026, 06:29 ET Making Sustainability Count on World Environment Day: How Beko Focuses on Lowering Water and Energy Consumption from Factories to Homes
2,000 R&D employees and hold more than 4,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the seventh consecutive year (based on the results
More news about: Beko
Jun 08, 2026, 05:15 ET 大昌行汽車正式更名為大昌行智行 邁向智慧出行生態新里程
www.dch.com.hk 有關大昌行智行 大昌行智行擁有超過60年汽車分銷及代理經驗，代理汽車類型廣泛，包括乘用車、商用車、電動巴士、特種車和豪華遊艇。在中國內地、香港、澳門、台灣、新加坡及緬甸經營逾 130 家 4S 特約店和陳列室。擁有廣泛的汽車相關業務組合，包括汽車維修、二手車買賣、零配件買賣、汽車租賃、融資租賃、保險仲介服務、遊艇銷售、機場地勤設備服務及工程等項目。 如有查詢，請聯絡：
More news about: 大昌行智行
Jun 08, 2026, 05:01 ET Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress
T-cell engagers (TCEs) targeting a single antigen face challenges with treatment failure due to antigen escape (low or lost CD19/CD20 expression), KT209's dual-antigen targeting mechanism is designed to prevent escape and improve clinical outcomes. Enhanced by a proprietary CD3 masking design, KT209 delivers
More news about: Kali Therapeutics
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Findings:Linear pharmacokinetics properties support once-daily oral administration: After a single oral dose, IBI3032's systemic exposure (AUCinf and Cmax) increased in an approximately dose-proportional manner across 0.3–6 mg dose range; peak
More news about: Innovent Biologics
Jun 08, 2026, 03:56 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients
More news about: Curasight
Jun 08, 2026, 03:53 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients
More news about: Curasight
Jun 08, 2026, 01:15 ET UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
false and misleading statements to the market. Upstart's "Model 22" AI frequently reacted poorly to macroeconomic signals. The Company overstated Model 22's overall accuracy. The Company's AI models were having a negative impact on its business performance. Based on these facts, the Company's public statements
More news about: The Schall Law Firm
Jun 08, 2026, 00:01 ET Winning firms will focus on what they can control, weather the rest, as triple-shock brakes private equity's latest revival --Bain & Company 2026 Midyear PE report
win, and to dig in to make it happen."Dislocations leave green and red zones for dealmakers as technology valuations slumpAmid 2026's 'Groundhog Day' dynamic of market revival followed by renewed retreat, Bain's analysis of the first-half's dislocations finds a general slowdown in
More news about: Bain & Company
Jun 07, 2026, 22:19 ET Unisound Releases U2: A Native Agentic Large Model Built for Execution, Capable of Autonomously Decomposing and Completing 100+ Steps in Complex Real-World Workflows
execution loop—moving beyond "providing answers" toward "getting work done."Top-tier performance in authoritative evaluations, demonstrating U2's core strengthIn the latest series of authoritative capability evaluations in China and overseas, U2 has entered the top tier of mainstream
More news about: Unisound
Jun 07, 2026, 22:03 ET Unisound Releases U2: A Native Agentic Large Model Built for Execution, Capable of Autonomously Decomposing and Completing 100+ Steps in Complex Real-World Workflows
execution loop—moving beyond "providing answers" toward "getting work done."Top-tier performance in authoritative evaluations, demonstrating U2's core strengthIn the latest series of authoritative capability evaluations in China and overseas, U2 has entered the top tier of mainstream
More news about: Unisound
Jun 07, 2026, 21:28 ET Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
treatment options, androgenetic alopecia remains an area of significant unmet medical need. We are encouraged by the Phase II results, which support CG2001's potential as a differentiated treatment option and its continued clinical development," said Baohui Yu, CEO of Dayspring Pharma.Dayspring Pharma
More news about: Dayspring Pharma
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
antibody discovery and engineering) and Ori®Armoring (structure-enhanced cell platform).Ori-C101's profile has the potential to support use in earlier lines of treatment, and GPC3's expression across multiple tumour types provides a strong scientific rationale for future indication expansion.
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET UPST Deadline: UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit
to negative macroeconomic signals in performing its risk-separation processes; (2) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (3) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative
More news about: THE ROSEN LAW FIRM, P. A.
Jun 07, 2026, 18:54 ET Bitmine Immersion Technologies 宣佈增額 A 系列永續優先股招股定價
上市。 倘上市申請獲批，公司預期交易將於 A 系列優先股首次發行日期後 30 天內開始。Moelis & Company 及 Cantor 擔任是次招股的聯席主賬簿管理方。是次招股依據一份於 2025 年 7 月 9 日向美國證券交易委員會（「SEC」）提交的 S-3 表格有效貨架登記聲明（檔案編號 333-288579）（「登記聲明」）進行。 是次招股只會透過招股章程補充文件以及登記聲明中所附的招股章程進行。 初步招股章程補充文件及隨附招股章程的電子版本，可在 SEC 網站
More news about: Bitmine Immersion Technologies, Inc.
Jun 07, 2026, 18:52 ET Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our
More news about: Kessler Topaz Meltzer & Check, LLP
Jun 07, 2026, 18:30 ET VolitionRx Announces Pricing of $4.6 Million Public Offering
closing conditions.The securities in the offering are being offered by Volition pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283088), initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2024, as amended, and declared effective
More news about: VolitionRx Limited
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
(REIMAGINE 1). Presented at the American Diabetes Association Scientific Sessions; June 5-8, 2026, New Orleans, LA.Buse J, Bajaj H, Dalskov S, et al. CagriSema versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a randomised, controlled, phase 3 study. Presented
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
StatesAbstract #1691-P, Presented Sunday, June 7A Meta-Analysis of Real-World Effectiveness of Glucagon-Like Peptide-1s Among Patients with Type 2 Diabetes in the United StatesAbstract #20-PUB, PublicationAbout the VESALIUS-CV TrialVESALIUS-CV
More news about: Amgen
Jun 07, 2026, 16:04 ET CERAVE VÍTA NA PRVÝCH GLOBÁLNYCH CENÁCH CERAWARDS VIAC AKO 100 OCENENÝCH TVORCOV OBSAHU Z 22 KRAJÍN
tvorcami.Značka CeraVe, vyvinutá v spolupráci s dermatológmi už od svojho založenia v roku 2005, už od svojich začiatkov kombinuje vedecky podloženú starostlivosť o pleť s osvetou. Jej základom sú tri esenciálne ceramidy totožné s tými, ktoré sa prirodzene nachádzajú v pokožke, hlboké odborné
More news about: CeraVe
Jun 07, 2026, 08:00 ET Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
[email protected] _______________________ Reference Novo Nordisk A/S. Data on file. © 2026 Novo Nordisk All rights reserved. US26SEMO01179 June 2026
More news about: NOVO NORDISK INC.
Jun 07, 2026, 07:14 ET 世界環境デーに、持続可能性を成果につなげる：工場から家庭まで、水とエネルギーの消費削減に取り組むBeko
電企業であり、2025年の連結売上高は107億ユーロに達しました。世界各地にあるBekoのR&D・デザインセンターおよびオフィス28か所には、2,000人を超えるR&D担当従業員が在籍しており、国際登録特許出願件数はこれまでに4,500件を超えています。同社は、S&P Global Corporate Sustainability Assessment（CSA）のDHP Household Durables（家庭用耐久財）業界において、7年連続で最高スコアを獲得しました（2025年10月16日付の結果に基づく）。**また、TIME誌とStatistaによる2025年版「世界で最も持続可能な企業（World's
More news about: Beko
Jun 07, 2026, 02:55 ET Bitmine Immersion Technologies annuncia il prezzo dell'offerta ampliata di azioni privilegiate perpetue di Serie A
l'offerta.L'offerta viene effettuata ai sensi di una dichiarazione di registrazione a scaffale efficace (shelf registration statement) valida sul modulo S-3 (numero di pratica 333-288579), depositata presso la Securities and Exchange Commission (la "SEC") il 9 luglio 2025 (la "Dichiarazione di registrazione").
More news about: Bitmine Immersion Technologies, Inc.
Jun 07, 2026, 02:41 ET BitMine Immersion Technologies anuncia a fixação do preço da oferta ampliada de ações preferenciais perpétuas da Série A
coordenadoras líderes conjuntas da oferta.A oferta está sendo realizada de acordo com uma declaração de registro prévia em vigor no Formulário S-3 (Arquivo nº 333-288579), arquivada na Comissão de Valores Mobiliários dos EUA (a "SEC") em 9 de julho de 2025 (a "Declaração de Registro"). A oferta
More news about: Bitmine Immersion Technologies, Inc.
Jun 07, 2026, 02:26 ET Bitmine Immersion Technologies anuncia el precio de ampliación de la emisión de acciones preferentes perpetuas de la Serie A
coordinadores conjuntos principales de la emisión.La emisión se ejecutará conforme a una declaración de autorización permanente vigente en el formulario S-3 (Expediente n.° 333-288579), presentado ante la Comisión de Bolsa y Valores ("SEC") el 9 de julio de 2025 (la "Declaración de autorización"). La emisión
More news about: Bitmine Immersion Technologies, Inc.